Invivyd, Inc. (IVVD)
Healthcare
- Fundamental
- 2
- Sentiment
- 1
- Technical
- 4
Do Nothing: fundamentalScore 2 and qualitativeScore 1 are below the required floor of 3; despite the short-term momentum breakout, IVVD also fails the $5M 20-day liquidity floor and shows a 5.77% overnight gap.
Company overview
Adagio Therapeutics, Inc. is a U.S.-based biopharmaceutical company focused on developing antibody-derived treatments for infectious diseases. Its lead candidate, ADG20, is in Phase 3 trials for COVID-19 management and prevention. The company collaborates with Adimab, LLC and the Scripps Research Institute for antibody identification and vaccine research.
Fundamental
weakThe company faces high fundamental risk due to substantial losses, negative cash flow, and going-concern disclosures.
Invivyd has real product revenue and very strong gross margins, but it remains a financing-dependent biotech with heavy losses, negative cash flow, and an explicit going-concern/substantial-doubt disclosure. Despite a net-cash balance sheet and high liquidity ratios, the recent cash drawdown and reliance on regulatory and clinical catalysts make the setup high risk; valuation and DCF/analyst targets look optimistic but are contingent on execution and funding.
Sentiment
very weakSentiment remains negative, with media focusing on financial risks and limited retail engagement.
Last ~14d coverage around Invivyd’s Aug 13 quarter update is mixed/near-neutral (polarity_score ≈ +0.01 vs 30–90d ≈ -0.07), suggesting stabilization after the July FDA/EUA-related negativity. Severe red-flag cap applied due to disclosed substantial-doubt/going‑concern language in recent filings.
Technical
goodShort-term momentum is strong, but the stock remains below key long-term averages and liquidity constraints limit tradability.
Score 4: short-term price action is strong with price above the SMA20, SMA50, EMA9, EMA21, and daily VWAP, while MACD has turned positive and ADX 41.88 confirms a powerful trend. The weak spots are that IVVD is still below its SMA200, the 20-day average remains under the 50-day, and momentum is already nearing overbought after a sharp, gap-prone burst higher.
You’re looking at 2026-08-22 — more than 2 trading days ago.
Subscribers saw this then, and see today’s score, verdict and trade plan now.
More Healthcare
Not financial advice. For informational and educational purposes only.